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Bronchioloalveolar Carcinoma Presenting as Chronic
Progressive Pulmonary Infiltrates in a Woman with HIV
A Diagnosis Worth Making
Todd M. Erickson, MD,* John R. Koeppe, MD,† York E. Miller, MD,‡ Rodney W. Stuart, MD,§
and D. Ross Camidge, MD, PhD
Absract: A 52-year-old woman with human immunodeficiency
virus (HIV) developed weight loss, cough, and breathing difficulties,
accompanied by extensive bilateral pulmonary infiltrates. A lengthy
infectious disease and autoimmune workup failed to reveal the
etiology or produce benefit. Expert pathology review raised the
possibility of pure bronchioloalveolar carcinoma. The patient was
treated with erlotinib and achieved a dramatic and prolonged re-
sponse to treatment. After 14 months a solitary lung nodule devel-
oped which was excised. This demonstrated an invasive adenocar-
cinoma with an activating epidermal growth factor receptor
mutation (exon 19 deletion). As this nodule had developed in the
presence of erlotinib, this deletion is only presumed to reflect the
initial driver of erlotinib sensitivity. Known acquired resistance
mechanisms were explored, but the lesion was negative for both
exon 20 T790M gatekeeper mutations and cMET gene copy number
alterations. An as yet unknown mechanism of acquired resistance is
therefore assumed to be involved in this case. We discuss the
diagnosis and treatment of lung cancer in HIV-positive populations
and review the general and specific characteristics of bronchioloal-
veolar carcinoma, including response to epidermal growth factor
receptor inhibitors, and known mechanisms of acquired resistance.
The predilection for lung cancer in HIV-positive patients, the diffuse
nature of bronchioloalveolar carcinoma that can mimic infectious
etiologies and the potential for dramatic responses to therapy make
this an important diagnosis to consider in this setting.
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(J Thorac Oncol. 2008;3: 1353–1355)
A 52-year-old African American woman with human im-munodeficiency virus (HIV) who was receiving highly
active antiretroviral therapy (HAART) developed a chronic
nonproductive cough accompanied by an interstitial infiltrate
in the left upper lung field on chest radiograph.
The patient had previously been diagnosed with diabe-
tes mellitus, controlled on two oral medications with no
known systemic complications. In regards to her HIV infec-
tion, at presentation her CD4 count was 610 cells/ul; HIV
RNA 4000 copies/ml. She had never been diagnosed with an
opportunistic infection and her CD4 count usually ranged 500
to 600/ul. She had briefly smoked cigarettes but had quit
more than 20 years ago (1 pack year of exposure).
After presentation, an extensive pulmonary evaluation
was performed over the next 22 months. Bronchoscopy was
performed on five separate occasions and a video-assisted
thoracoscopic surgery wedge biopsy of the right lower lobe.
Cytology from multiple sputum samples and bronchial wash-
ings failed to reveal malignant cells. Bronchoscopic evalua-
tion revealed copious serous secretions without evidence of
any endobronchial lesion. Transbronchial biopsy specimens
demonstrated nonspecific inflammation only. The wedge re-
section revealed acute bronchopneumonia, organizing pneu-
monia, and rare poorly formed granulomas.
More than 10 separate sputum and bronchial specimens
were sent for acid fast bacilli stain and culture, fungal culture,
aerobic and anaerobic bacterial culture, and viral cultures but
no specific pathogens were identified. Extensive laboratory
evaluations were performed for atypical causes of pneumonia
without a clear etiology being found.
While these repeated evaluations were being per-
formed, the patient continued to deteriorate clinically with
progressive hypoxia, worsening of her pulmonary infiltrates
and weight loss of more than 40 lbs. The patient was treated
with multiple courses of antibiotics and empiric steroids
without significant improvement in her pulmonary disease.
Cryptococcus neoformans was cultured from a bronchial
washing on one occasion and the patient was started on
treatment with fluconazole and subsequently liposomal am-
photericin B without clinical benefit.
Despite the previous bronchial washings and biopsies
being reported as showing no evidence of malignant cells,
review of these specimens at a multidisciplinary pulmonary
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conference with expert lung cancer pathologists present
raised the possibility that the patient’s pulmonary disease
could be due to bronchioloalveolar carcinoma (BAC). Sub-
sequently, repeat bronchoscopy with multiple transbronchial
biopsies of the left upper lobe revealed alveolar cells with
histologic features consistent with pure BAC(Figure 1).
The patient was seen in consultation by medical oncol-
ogy. Positron emission tomography/computed tomography
(CT) imaging revealed extensive patchy infiltrates involving
all lobes of both lungs as well as an area of more dense
consolidation of the left upper lobe with an standard uptake
value of 5.2 at its center. There was no evidence of extratho-
racic spread or significant lymphadenopathy. The area of
potential BAC on the last set of biopsies was considered too
small to characterize further, and no additional molecular
tests were conducted at that time. The patient was empirically
started on an oral regimen of erlotinib 150 mg daily which
was well tolerated and caused only a mild acneiform rash.
After treatment for 3.5 months, a chest CT was repeated
and demonstrated dramatic improvement with near resolution
of pulmonary infiltrates (Figure 2). The patient clinically
improved with resolution of cough and hypoxia along with a
weight gain of 40 pounds. After 14 months of therapy with
erlotinib, the patient developed a left lower lobe lung nodule
that increased in size to 12 mm and was found to have a
standard uptake value of 4.4 on positron emission tomogra-
phy/CT. The suspicious lesion was excised through video-
assisted thoracoscopic surgery wedge resection revealing a
moderately differentiated adenocarcinoma which was EGFR
positive by immunohistochemistry and demonstrated in-
creased EGFR gene copy number by fluorescent in situ
hybridization (FISH). Additional molecular correlates re-
vealed that the tumor possessed an activating exon 19 dele-
tion in EGFR (with wild type sequence in exons 20 and 21),
was k-ras wild type, had no evidence of cMET gene copy
number alteration by FISH, but did have increased Her2 gene
copy number by FISH with modest Her2 expression (2) by
immunohistochemistry. The patient recovered quickly from
the operation and continues on erlotinib.
DISCUSSION
Lung cancer remains an important differential consid-
eration when investigating persistent pulmonary infiltrates in
individuals infected with HIV. Several investigators have
reported an increased incidence of lung cancer among HIV-
positive populations in the HAART era.1–3 Although some of
this increased risk may be attributed to the higher prevalence
of smoking, HIV has independently been associated with an
increased risk of developing lung carcinoma and this risk
seems to be unrelated to the level of HIV-induced immuno-
suppression.4
FIGURE 2. Near complete response to therapy with erlo-
tinib. Computed tomography (CT) chest at initiation of
treatment with erlotinib (left) and after 6 months of therapy
with erlotinib (right).
FIGURE 1. A, (H&E 200X) Bronchioloalveolar carcinoma
within the transbronchial biopsy. Alveolar septa are lined by
tall, columnar cells with mild nuclear pleomorphism and hy-
perchromasia, which project into spaces with papillary pro-
jections (arrow). The underlying lung architecture (right) is
relatively preserved with thin vascular septa lined by benign
pneumocytes. B, (H&E 400X) Bronchioloalveolar carcinoma
within the transbronchial biopsy. The features of nuclear ple-
omorphism and hyperchromasia are better demonstrated on
this high power view.
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The combination of HIV infection and lung carcinoma
generally portends a grim prognosis. Multiple small retro-
spective case studies have reviewed survival of HIV-positive
patients compared with matched HIV-negative controls. The
median survival of HIV-positive patients with lung cancer
was approximately 4.5 months with 1 year survival of 10%.
HIV-negative controls had a median survival of 10 months
with 1 year survival of approximately 40%.5 Hakimian et al.6
recently performed a retrospective analysis of their experi-
ence treating 34 patients with HIV and lung cancer in the
HAART era. Their experience supported previous survival
findings and there seemed to be a trend towards worse survival
among patients with CD4 counts200. Unfortunately, random-
ized prospective studies have not been performed to assess the
relative efficacy and toxicity of different chemotherapies in an
HIV-positive population with lung cancer.
While there is little empiric data to guide chemotherapy
for lung cancer in HIV infected patients, several investigators
have studied the use of targeted EGFR inhibitors, such as
erlotinib, in BAC. Since pure BAC is a relatively rare entity
and it is difficult to rule out a small component of invasive
adenocarcinoma, most clinical studies evaluating efficacy of
treatment have included adenocarcinomas with any features
of BAC. Although a subgroup analysis of Eastern Coopera-
tive Oncology Group 1594 revealed a lower response rate to
standard chemotherapy doublets in patients with BAC com-
pared with other types of non-small cell lung cancer (6%
versus 20%), there have not been any prospective randomized
trials assessing the efficacy of different standard doublet
chemotherapies in patients with BAC.7 Nevertheless, there
have been two trials which have specifically evaluated the
efficacy of EGFR inhibitors in BAC. In Southwest Oncology
Group 0126, gefitinib was evaluated in 90 patients with some
histologic component of BAC and demonstrated a 19% re-
sponse rate in chemo-naive patients and 9% in chemotherapy
pretreated patients.8 Some of these patients had complete
responses. Similarly, erlotinib has been evaluated in a phase
II study of 159 patients with advanced stage BAC lung
carcinoma with overall response rate of 24% and an impres-
sive 40% response rate in never smokers.9 In this patient,
on-treatment progression of a solitary nodule after 14 months
of erlotinib prompted excision revealing an invasive adeno-
carcinoma with an activating EGFR mutation, EGFR gene
amplification and Her2 gene amplification. Nevertheless, as
all of these factors are normally associated with sensitivity to
EGFR inhibition to varying degrees, the assumption is that
this identifies the drivers present in the underlying BAC and
responsible for the initial dramatic response, and that a
secondary acquired resistance factor must also be present to
drive the new BAC to adenocarcinoma progression.10 In
previous human studies, approximately 50% of cases of
acquired resistance to EGFR inhibitors are due to the expres-
sion of the so-called gate-keeper T790M mutation in exon 20,
however, this did not seem to be the case here.10 Approxi-
mately 10 to 20% of cases of acquired resistance have
recently been ascribed to cMET gene amplification, but again
this did not seem to be the mechanism used in this case.10
As this case illustrates, the lepidic pattern of growth of
BAC may produce extensive diffuse pulmonary infiltrates
that can mimic those with infectious etiologies, delaying the
diagnosis, particularly in those considered to be most at risk
from infection. Selected patients with HIV and lung carci-
noma can clearly have a dramatic response to modern anti-
cancer therapies. Given the apparent increased risk of lung
cancer in those with HIV, dedicated clinical trials of the
tolerability and efficacy of different anticancer agents should
be considered in this unique, but increasing, population.
Information on whether the prevalence of known molecular
drivers in non-small cell lung cancer differ significantly
between those with and without HIV remains unknown.
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